Evidence map›Paper›PMID 42907518›Full record

ReviewNature2026

Multimodal precision diagnostics in clinical xenotransplantation.

Raphael P H Meier, Erwan Morgand, Fariza Mezine, Michael Mengel, Massimo Mangiola, Muhammad M Mohiuddin, Robert A Montgomery, Alexandre Loupy

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Raphael P H Meier *University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9050-0436
Erwan Morgand *Paris Institute for Transplantation and Organ Regeneration (PITOR), Université Paris Cité, PARCC INSERM, Paris, France.ORCID http://orcid.org/0000-0002-1064-8770
Fariza MezineParis Institute for Transplantation and Organ Regeneration (PITOR), Université Paris Cité, PARCC INSERM, Paris, France.
Michael MengelUniversity of Alberta, Edmonton, Alberta, Canada.
Massimo MangiolaNYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0002-5406-4005
Muhammad M MohiuddinUniversity of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4654-783X
Robert A MontgomeryNYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0003-2728-4552
Alexandre LoupyParis Institute for Transplantation and Organ Regeneration (PITOR), Université Paris Cité, PARCC INSERM, Paris, France. alexandre.loupy@inserm.fr.ORCID http://orcid.org/0000-0003-3388-7747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent breakthroughs in pig-to-human xenotransplantation have successfully prevented hyperacute rejection of kidney, heart, liver and lung xenografts, marking a milestone long considered a critical barrier. However, these major advances also brought new challenges into focus, as immune-mediated graft injuries including antibody-mediated rejection, T cell-mediated rejection and innate immune activation have been observed in most xenotransplantation procedures to date. Detection and management of these injuries remain a critical bottleneck, as conventional histopathology and standard clinical monitoring lack the sensitivity required to identify subclinical injury early enough to guide timely intervention. This diagnostic gap underscores an urgent need for the development of advanced, multimodal precision diagnostic frameworks to enhance immune surveillance, which will be essential for standardizing clinical protocols and enabling pathogenesis-driven therapeutic intervention. This approach will inform both immunosuppressive regimens and future gene editing strategies aimed at engineering rejection-resistant porcine organs, ultimately prolonging graft survival. Broad adoption of such an integrative strategy will be essential to transition xenotransplantation from an experimental intervention into a safe, scalable and patient-centred clinical therapy. In this Review, we synthesize recent progress in xenotransplantation and position multimodal precision diagnostics as a pivotal strategy to address the remaining immunological and clinical barriers to widespread clinical implementation.

Indexed as

Diagnostic Techniques and ProceduresGraft RejectionTransplantation, HeterologousAnimalsGraft SurvivalHumansPrecision MedicineSwineT-Lymphocytes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.